Suppr超能文献

对《一种迭代方法指导法比霉素（FabI抑制剂，一种对耐药革兰氏阴性感染有效的后期抗生素候选药物）的发现》的修正

Correction to "An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with Efficacy against Drug-Resistant Gram-Negative Infections".

作者信息

Parker Erica N, Cain Brett N, Hajian Behnoush, Ulrich Rebecca J, Geddes Emily J, Barkho Sulyman, Lee Hyang Yeon, Williams John D, Raynor Malik, Caridha Diana, Zaino Angela, Rohde Jason M, Zak Mark, Shekhar Mrinal, Muñoz Kristen A, Rzasa Kara M, Temple Emily R, Hunt Diana, Jin Xiannu, Vuong Chau, Pannone Kristina, Kelly Aya M, Mulligan Michael P, Lee Katie K, Lau Gee W, Hung Deborah T, Hergenrother Paul J

机构信息

Department of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.

Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.

出版信息

ACS Cent Sci. 2022 Sep 28;8(9):1362. doi: 10.1021/acscentsci.2c00969. Epub 2022 Sep 6.

DOI:10.1021/acscentsci.2c00969
PMID:36188352
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9523767/
Abstract

[This corrects the article DOI: 10.1021/acscentsci.2c00598.].

摘要

[本文更正了文章的数字对象标识符：10.1021/acscentsci.2c00598。]

相似文献

1
Correction to "An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with Efficacy against Drug-Resistant Gram-Negative Infections".对《一种迭代方法指导法比霉素（FabI抑制剂，一种对耐药革兰氏阴性感染有效的后期抗生素候选药物）的发现》的修正
ACS Cent Sci. 2022 Sep 28;8(9):1362. doi: 10.1021/acscentsci.2c00969. Epub 2022 Sep 6.
2
An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with Efficacy against Drug-Resistant Gram-Negative Infections.一种迭代方法指导发现法比霉素（FabI抑制剂），这是一种后期抗生素候选药物，对耐药革兰氏阴性菌感染有效。
ACS Cent Sci. 2022 Aug 24;8(8):1145-1158. doi: 10.1021/acscentsci.2c00598. Epub 2022 Aug 10.
3
Discovery of a novel and potent class of FabI-directed antibacterial agents.发现一类新型强效的针对FabI的抗菌剂。
Antimicrob Agents Chemother. 2002 Oct;46(10):3118-24. doi: 10.1128/AAC.46.10.3118-3124.2002.
4
Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor.新型细菌烯酰-酰基载体蛋白还原酶（FabI）抑制剂CG400549的抗葡萄球菌活性
J Antimicrob Chemother. 2007 Sep;60(3):568-74. doi: 10.1093/jac/dkm236. Epub 2007 Jul 2.
5
A Novel Benzoxaborole Is Active against Escherichia coli and Binds to FabI.新型苯并硼氧烷对大肠杆菌具有活性，并与 FabI 结合。
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0262220. doi: 10.1128/AAC.02622-20.
6
Implementation of permeation rules leads to a FabI inhibitor with activity against Gram-negative pathogens.渗透规则的实施导致了一种对革兰氏阴性病原体具有活性的 FabI 抑制剂。
Nat Microbiol. 2020 Jan;5(1):67-75. doi: 10.1038/s41564-019-0604-5. Epub 2019 Nov 18.
7
Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.FabI抑制剂，一种细菌脂肪酸生物合成途径中的酶类药物靶点。
Acc Chem Res. 2008 Jan;41(1):11-20. doi: 10.1021/ar700156e.
8
Rational design of broad spectrum antibacterial activity based on a clinically relevant enoyl-acyl carrier protein (ACP) reductase inhibitor.基于一种临床相关的烯酰基辅酶 A （ACP）还原酶抑制剂的广谱抗菌活性的合理设计。
J Biol Chem. 2014 Jun 6;289(23):15987-6005. doi: 10.1074/jbc.M113.532804. Epub 2014 Apr 16.
9
Facilitating Compound Entry as a Means to Discover Antibiotics for Gram-Negative Bacteria.促进化合物进入以发现针对革兰氏阴性菌的抗生素。
Acc Chem Res. 2021 Mar 16;54(6):1322-1333. doi: 10.1021/acs.accounts.0c00895. Epub 2021 Feb 26.
10
Correction to Remdesivir: A Review of Its Discovery and Development Leading to Human Clinical Trials for Treatment of COVID-19.《瑞德西韦的修正：对其发现与研发历程的回顾，该历程导向了针对治疗 COVID-19 的人体临床试验》
ACS Cent Sci. 2020 Jun 24;6(6):1009. doi: 10.1021/acscentsci.0c00747. Epub 2020 Jun 16.

引用本文的文献

1
A comprehensive computer-based assessment of Deacetylnomilin as an inhibitor for antibiotic-resistant genes identified from the whole genome sequence of the multidrug-resistant Enterobacter cloacae isolate 1382.基于计算机的对去乙酰诺米林作为从多重耐药阴沟肠杆菌分离株1382全基因组序列鉴定出的抗生素抗性基因抑制剂的全面评估。
Mol Divers. 2024 Dec 20. doi: 10.1007/s11030-024-11077-3.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验